# A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

> **NCT05593445** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 61 (actual)

## Conditions studied

- Lichen Sclerosus

## Interventions

- **DRUG:** Ruxolitinib cream
- **DRUG:** Vehicle cream

## Key facts

- **NCT ID:** NCT05593445
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-18
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-12-21
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593445, "A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05593445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*